2022-05-24 19:54:19来源：医脉通阅读：11次
医脉通编辑整理，未经授权请勿转载
一年一度的全球肿瘤界盛会-美国临床肿瘤学会（ASCO）年会将于当地时间6月3日-6月7日召开。医脉通特梳理了
临床科学研讨会
01.摘要号：106
一项关于AK104（抗PD1和抗CTLA4的双特异性抗体）与标准治疗联合用于持续性、复发性或转移性
标题：A study of AK104 (an anti-PD1 and anti-CTLA4 bispecific antibody) combined with standard therapy for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (R/M CC).
报告人：王静
单位：湖南省肿瘤医院
02.摘要号：5510
开放标签、非随机、多中心的II期临床试验：
标题：An open label, nonrandomized, multisite phase II trial combining bevacizumab, atezolizumab, and rucaparib for the treatment of previously treated recurrent and progressive endometrial cancer.
报告人：William Hampton Bradley, MD
单位：Froedtert and the Medical College of Wisconsin
口头报告
01.摘要号：LBA5500
随机、双盲、III期ATHENA-MONO（GOG-3020/ENGOT-ov45）研究：含铂类化疗一线治疗后，rucaparib单药对比安慰剂维持治疗卵巢癌的疗效评估
标题：ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.
报告人：Bradley J. Monk, MD
单位：GOG Foundation, University of Arizona College of Medicine, Creighton University School of Medicine
02.摘要号：5501
I/II期研究：ruxolitinib与一线新辅助和术后治疗晚期上皮性卵巢癌、输卵管癌或原发性腹膜癌
标题：A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.
报告人：Charles N. Landen, MD
单位：Univ of Texas MD Anderson Cancer Ctr
03.摘要号：LBA5503
3臂、随机、开放标签的II期研究：选择性糖皮质激素受体调节剂（relacorilant）联合
标题：Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
报告人：Nicoletta Colombo, MD
单位：University of Milan-Bicocca, European Institute of Oncology (IEO) IRCCS
04.摘要号：5506
KEYNOTE-826研究的亚组分析：
标题：Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
报告人：Krishnansu Sujata Tewari, MD, F
单位：David Geffen School of Medicine at UCLA
05.摘要号：5507
ENGOT Cx8/GOG 3024/innovaTV 205研究：Tisotumab vedotin（TV）联合帕博利珠单抗（pembro）一线（1L）治疗复发或转移性宫颈癌（r/mCC） 的中期结果
标题：Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.
报告人：Domenica Lorusso, MD, PhD
单位：Fondazione Policlinico Gemelli IRCCS
壁报讨论
01.摘要号：5514
海报：393
随机II期NCI试验#10150研究：贝伐珠单抗和每周anetumab ravtansine或每周紫杉醇治疗铂类耐药或难治性卵巢癌
标题：A randomized phase II study of bevacizumab and weekly anetumab ravtansine or weekly paclitaxel in platinum-resistant or refractory ovarian cancer NCI trial#10150.
报告人：Stephanie Lheureux, MD, PhD
单位：Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network
02.摘要号：5515
海报：394
II期信号寻找试验IGNITE研究：adavosertib靶向治疗复发的、人细胞周期素E1过表达伴或不伴基因扩增的高级别、浆液性卵巢癌
标题：IGNITE: A phase II signal-seeking trial of adavosertib targeting recurrent high-grade, serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
报告人：George Au-Yeung, PhD, MBBS
单位：Department of Medical Oncology, Peter MacCallum Cancer Centre
03.摘要号：5517
海报：396
II期LIO-1研究（NCT04042116；ENGOT-GYN3/AGO/LIO）：lucitanib联合
标题：Efficacy and safety of lucitanib + nivolumab in patients with advanced gynecologic malignancies: Phase 2 results from the LIO-1 study (NCT04042116; ENGOT-GYN3/AGO/LIO).
报告人：Manish R. Patel, MD
单位：Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute
04.摘要号：5522
海报：401
II期临床试验：
标题：A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.
报告人：Lauren P. Cobb, MD
单位：Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center
壁报展示
01.摘要号：5536
海报：415
II期临床试验：
标题：Overall survival results from a phase II trial of anlotinib plus sintilimab in patients with recurrent advanced cervical cancer.
报告人：徐沁
单位：福建省肿瘤医院
02.摘要号：5543
海报：422
II期非随机临床试验：帕博利珠单抗联合安罗替尼治疗难治性或复发性高级别浆液性卵巢癌的疗效和安全性
标题：Efficacy and safety of pembrolizumab in combination with anlotinib in the treatment of refractory or recurrent high-grade serous ovarian cancer: A phase 2 nonrandomized clinical trial.
报告人：Jianqiao Xian, MD
单位：青岛大学附属医院
03.摘要号：5551
海报：430
III期PRIME研究的亚组分析：
标题：Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy.
报告人：尹如铁
单位：四川大学华西第二医院
04.摘要号：5591
海报：467
单臂II期试验的中期结果：
标题：Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least first-line therapy: Interim results of a single-arm phase II trial.
报告人：王华英
单位：复旦大学上海医学院
05.摘要号：TPS5607
海报：480a
单臂、多中心、II期研究：安罗替尼联合卡铂/紫杉醇一线治疗和安罗替尼维持治疗新诊断的晚期卵巢癌患者
标题：Frontline therapy of anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib in patients with newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study.
报告人：Yi Jiang
单位：江苏省人民医院
备注：排名不分先后，按照摘要号进行
如有遗漏或任何问题，请给我们留言~
参考来源：https://meetings.asco.org/meetings/2022-asco-annual-meeting